Vioxx litigation update
Executive Summary
Merck is named as defendant in 2,300 Vioxx-related lawsuits, including 4,600 plaintiff groups alleging personal injuries following the use of the COX-2 inhibitor. The first trials are scheduled for May 23 in Alabama and May 31 in Texas. Merck has $675 mil. in reserve to cover the legal costs associated with the withdrawal of Vioxx in September 2004 (1"The Pink Sheet" Jan. 31, 2005, p. 7)...
You may also be interested in...
Merck Sets $604 Mil. Vioxx Legal Defense Reserve; PR Battles Continue
Merck will take a $604 mil. charge in the fourth quarter to establish a reserve for its defense of Vioxx litigation, an amount roughly equivalent to Singulair quarterly sales
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.